Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.55 |
| ▸ | GAA | P10253 | 3/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 5/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3765882 | 0.86 | TSHR (0.49) | SMN1; SMN2GAANPSR1HPGDKDM4E | |
| SCHEMBL3757565 | 0.85 | SMN1; SMN2 (0.48) | CYP2C9CYP2C19SMN1; SMN2GAANPSR1 | |
| SCHEMBL3759129 | 0.84 | TSHR (0.51) | SMN1; SMN2GAAHPGDKDM4EHSD17B10 | |
| SCHEMBL3759186 | 0.82 | POLB (0.59) | CYP2C9CYP2C19MAPTKDM4EALDH1A1 | |
| SCHEMBL7495196 | 0.78 | SMN1; SMN2 (0.63) | CYP2C9CYP2C19SMN1; SMN2GAAMAPT | |
| SCHEMBL3122081 | 0.76 | GAA (0.47) | CYP2C9CYP2C19SMN1; SMN2GAAHPGD | |
| SCHEMBL3122088 | 0.76 | FKBP1A (0.51) | SMN1; SMN2MAPTHPGDKDM4EALDH1A1 | |
| SCHEMBL963770 | 0.76 | LMNA (0.65) | CYP2C19MAPTHPGDALDH1A1TSHR | |
| SCHEMBL1848179 | 0.76 | CYP2C9 (1.00) | CYP2C9CYP2C19SMN1; SMN2GAANPSR1 | |
| SCHEMBL3129274 | 0.74 | LMNA (0.49) | CYP2C9CYP2C19SMN1; SMN2NPSR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110245238-A1 | Novel Soluble 1,4 Benzodiazepine Compounds and Stable Salts Thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-10-06 | — | — | US | claimed |
| US-20110009393-A1 | Novel Soluble 1,4 Benzodiazepine Compounds and Stable Salts Thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-01-13 | — | — | US | claimed |
| US-7759338-B2 | Soluble 1,4 benzodiazepine compounds and stable salts thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-07-20 | — | — | US | claimed |
| EP-2152080-A1 | NOVEL SOLUBLE 1,4 BENZODIAZEPINE COMPOUNDS AND STABLE SALTS THEREOF | The Regents of the University of Michigan (US) | 2010-02-17 | — | — | EP | claimed |
| WO-2008133635-A1 | NOVEL SOLUBLE 1,4 BENZODIAZEPINE COMPOUNDS AND STABLE SALTS THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2008-11-06 | — | — | WO | claimed |
| US-20080064686-A1 | Novel soluble 1,4 benzodiazepine compounds and stable salts thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2008-03-13 | — | — | US | claimed |
| EP-0770079-B1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO (JP) | 2003-02-12 | — | — | EP | claimed |
| US-20020107251-A1 | Heterobicyclic derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-08-08 | — | — | US | claimed |
| US-6426345-B1 | PHOSPHODIESTERASE INHIBITORS; ANTIINFLAMMATORY AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-07-30 | — | — | US | claimed |
| EP-0770079-A1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-05-02 | — | — | EP | claimed |
| WO-1996001825-A1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-01-25 | — | — | WO | claimed |
| EP-2029570-B1 | FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2014-10-15 | — | — | EP | disclosed |
| US-8455477-B2 | Therapeutic compounds | MERCK SHARP & DOHME CORP. (US) | 2013-06-04 | — | — | US | disclosed |
| US-8324204-B2 | Fused thiophene derivatives as kinase inhibitors | UCB PHARMA SA (BE) | 2012-12-04 | — | — | US | disclosed |
| US-20110245238-A1 | Novel Soluble 1,4 Benzodiazepine Compounds and Stable Salts Thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-10-06 | — | — | US | disclosed |
| EP-0770079-B1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO (JP) | 2003-02-12 | — | — | EP | disclosed |
| US-20020107251-A1 | Heterobicyclic derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-08-08 | — | — | US | disclosed |
| US-6426345-B1 | PHOSPHODIESTERASE INHIBITORS; ANTIINFLAMMATORY AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-07-30 | — | — | US | disclosed |
| EP-0920867-A1 | Pyrido[2,3-a]pyrazine derivatives as PDE-IV and TNF inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-06-09 | — | — | EP | disclosed |
| WO-1996001825-A1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245238-A1 | Novel Soluble 1,4 Benzodiazepine Compounds and Stable Salts Thereof | GABRA4, BAD, GABRA1 | CYP2C9 1869/4885CYP2C19 1569/4885SMN1; SMN2 2728/4885 |
| US-20080064686-A1 | Novel soluble 1,4 benzodiazepine compounds and stable salts thereof | GABRA4, BAD, GABRA1 | CYP2C9 1869/4885CYP2C19 1569/4885SMN1; SMN2 2728/4885 |
| US-20110009393-A1 | Novel Soluble 1,4 Benzodiazepine Compounds and Stable Salts Thereof | GABRA4, BAD, GABRA1 | CYP2C9 1869/4885CYP2C19 1569/4885SMN1; SMN2 2728/4885 |
| US-20020107251-A1 | Heterobicyclic derivatives | ARSA, ARRB1, SULT2A1 | CYP2C9 140/4885CYP2C19 125/4885SMN1; SMN2 3337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.